TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2246313
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic bowel preparation)
Study: 30136741
Drug: Immediate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate or delayed periodontal treatment (full-mouth non-surgical scaling and root planing, systemic antibiotics, and oral health instructions)
Study: 30136741
Drug: Immediate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate or delayed periodontal treatment
Study: 27863480
Drug: Patient-centered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered cognitive behavioral therapy intervention group
Study: 22162534
Drug: GSK1521498 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (2, 5, and 10 mg) administered once daily for 10 days
Study: 22162534
Drug: GSK1521498 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (10 mg) administered once daily for 10 days
Study: 18386046
Drug: EBM course
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBM course in combination with case method learning sessions (CMLSs)
Study: 7723464
Drug: Data base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data base approach to assess relative efficacy of alternative therapies
Study: 7723464
Drug: Recording reasons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recording reasons for therapy selection
Study: 2107581
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro‐ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR)
Study: 7410745
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Theophylline, Terbutaline, Prednisone)
Study: 30269276
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 leucovorin (LV)
Study: 30269276
Drug: 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2 leucovorin (LV)
Study: 30269276
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 leucovorin (LV)
Study: 30269276
Drug: 0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/m2 leucovorin (LV) (untreated)
Study: 26818098
Drug: EQ‐5D‐3 L
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ‐5D‐3 L
Study: 23432730
Drug: Brinzolamide-timolol fixed
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brinzolamide-timolol fixed combination
Study: 21115134
Drug: GoLytely (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoLytely (4 L split-dose)
Study: 21115134
Drug: MiraLAX with
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiraLAX with lubiprostone (24 μg)
Study: 21115134
Drug: MiraLAX with
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiraLAX with bisacodyl (10 mg)
Study: 18932058
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with 500 mg alpha‐tocopherol and 2 g vitamin C for 12 weeks
Study: 11342473
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg IVIG
Study: 1411634
Drug: Combination cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination cisplatin and carboplatin plus doxorubicin/hexamethylmelamine/cyclophosphamide
Study: 1411634
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (350 mg/m2 on day 1) plus oral cyclophosphamide (100 mg/m2 days 2 to 6)
Study: 1411634
Drug: High-dose carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin (800 mg/m2)
Study: 26951379
Drug: Fotemustine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine (75 mg/m² on days 1, 8, and 15, then 100 mg/m² every 3 weeks after a 35-day interval)
Study: 24702886
Drug: deep inhalation
Normalized name: Deep Sea Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: deep inhalation methacholine challenge
Study: 20703472
Drug: Intrasphincteric injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasphincteric injection of botulinum toxin (BT)
Study: 19017911
Drug: G. biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. biloba (120 mg twice daily)
Study: 16018146
Drug: Intranasal 17
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17 beta‐estradiol 300 microg daily
Study: 8923016
Drug: Chemopreventive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemopreventive agents
Study: 1553935
Drug: Alprazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25 mg, three times a day)
Study: 3159407
Drug: diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 0.2 mg kg‐1 i.v.
Study: 3159407
Drug: midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.05 mg kg‐1 i.v.
Study: 3159407
Drug: midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.1 mg kg‐1 i.v.
Study: 23448285
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment (pelvic floor muscle training, delayed voiding, urge suppression techniques)
Study: 23448285
Drug: Antimuscarinic drug
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic drug therapy (extended-release oxybutynin)
Study: 23448285
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment (for those with ≥2 episodes nocturia at baseline)
Study: 23448285
Drug: Antimuscarinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic therapy (for those with ≥2 episodes nocturia at baseline)
Study: 18799365
Drug: C&G
Normalized name: Cefuroxime and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C&G
Study: 11677204
Drug: Antibiotics (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week)
Study: 11677204
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg omeprazole twice a day and identical placebos for 1 week)
Study: 11677204
Drug: H. pylori-negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori-negative group (open label 20 mg omeprazole twice a day for 1 week)
Study: 29912844
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of IXIARO administered 12 months after primary immunization
Study: 29912844
Drug: No booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: No booster dose
Study: 29912844
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of IXIARO
Study: 24627290
Drug: Gemigliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin (50 mg once daily) and Metformin (1,000 mg twice a day)
Study: 24627290
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg twice a day)
Study: 22278162
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (hot pack, ultrasound therapy, friction massage)
Study: 11602481
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave treatment (ESWT)
Study: 12456445
Drug: Tramadol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infusion (1 mg/kg loading dose, 0.2 mg/kg/h postoperative infusion)
Study: 12456445
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA alone (control group)
Study: 2031819
Drug: i.v. atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. atropine 0.5 mg
Study: 2031819
Drug: i.v. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. saline 1 ml
Study: 2031819
Drug: i.v. lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. lignocaine 3 ml with adrenaline 15 micrograms
Study: 2031819
Drug: adrenaline test
Approvals — FDA: no, EMA: no, PMDA: no
Description: adrenaline test dose
Study: 7404171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of transbronchial biopsy, alveolar lavage, and radiography
Study: 31980506
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate lozenges (13 mg elemental zinc, taken six times per day for a maximum of 5 days)
Study: 31980506
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (sucrose octa-acetate, taken six times per day for a maximum of 5 days)
Study: 28628688
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment and nutraceutical (Group 2)
Study: 28628688
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (Group 1)
Study: 15690714
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication therapy; specific dosage and duration not mentioned.
Study: 8083147
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg
Study: 956343
Drug: Meclastine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclastine (oral administration for three days)
Study: 956343
Drug: Dexchlorpheniramine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine (intravenous infusion)
Study: 7788012
Drug: Insulin hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin hypoglycemia
Study: 28522450
Drug: Other glucose-lowering
Normalized name: Other blood glucose lowering drugs, excl. insulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other glucose-lowering drugs
Study: 21142844
Drug: Nucleoside and
Normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV) during first trimester
Study: 21142844
Drug: Nucleoside and
Normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV) after first trimester
Study: 21142844
Drug: Nucleoside and
Normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV)
Study: 17336514
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg daily
Study: 15062131
Drug: 125I episcleral
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I episcleral plaque radiotherapy (EPRT) with median dose of 80.0 Gy
Study: 15062131
Drug: 125I episcleral
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I episcleral plaque radiotherapy (EPRT) with median dose of 60.8 Gy
Study: 6371152
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 micrograms per dose)
Study: 25912588
Drug: valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (80 mg/d) and atorvastatin (20 mg/d)
Study: 25912588
Drug: benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (10 mg/d) and atorvastatin (20 mg/d)
Study: 23015654
Drug: IGF‐I serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I serum levels in men (137 ± 69 ng/ml for AD)
Study: 23015654
Drug: IGFBP‐3 serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGFBP‐3 serum levels in men (3675 ± 1542 ng/ml for AD)
Study: 23015654
Drug: IGFBP‐3 serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGFBP‐3 serum levels in women (3781 ± 1351 ng/ml for AD)
Study: 19562320
Drug: Reniale (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reniale (autologous tumour cell lysate vaccination therapy)
Study: 6144974
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjuvant treatment)
Study: 11523669
Drug: Hypervolemic hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypervolemic hypertensive hemodilution fluid therapy
Study: 11523669
Drug: Normovolemic fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic fluid therapy
Study: 3284630
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/day) for six weeks
Study: 17692728
Drug: Suspension formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension formulation of acyclovir 400 mg
Study: 17692728
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of acyclovir 400 mg
Study: 14757326
Drug: CRH(1)-receptor-antagonist R121919
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH(1)-receptor-antagonist R121919 (higher doses)
Study: 14757326
Drug: CRH(1)-receptor-antagonist R121919
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH(1)-receptor-antagonist R121919 (lower doses)
Study: 14757326
Drug: CRH(1)-receptor-antagonist R121919
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH(1)-receptor-antagonist R121919
Study: 9709744
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (standard intensity)
Study: 9709744
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (less than standard intensity)
Study: 3135010
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment for women
Study: 29407665
Drug: L'/L' homozygotes
Approvals — FDA: no, EMA: no, PMDA: no
Description: L'/L' homozygotes
Study: 26754071
Drug: FENIX magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FENIX magnetic sphincter augmentation (MSA)
Study: 19878097
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (CT group)
Study: 9609409
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen intravenously (i.v.)
Study: 30676200
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (infusion resulting in an arterial blood alcohol concentration of 80 mg%)
Study: 30676200
Drug: Placebo condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo condition (saline infusion)
Study: 25873213
Drug: Bevacizumab (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (standard dose, monthly review)
Study: 25873213
Drug: Bevacizumab (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (low dose, monthly review)
Study: 25873213
Drug: Bevacizumab (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (standard dose, two-monthly review)
Study: 25873213
Drug: Bevacizumab (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (low dose, two-monthly review)
Study: 23001556
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg, increased to 70 mg over 4 weeks and maintained for another 4 weeks
Study: 21425570
Drug: Integrative medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative medical therapy (Chinese drugs)
Study: 21425570
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic therapy only)
Study: 19178385
Drug: Endurance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance exercise (thrice weekly 45‐min intervals)
Study: 19178385
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (three 45‐min episodes of stretching, balance training and coordination)
Study: 16172624
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g of creatine monohydrate daily for 6 days)
Study: 16172624
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, daily for 6 days)
Study: 14520721
Drug: Long-acting β2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-adrenoceptor agonists (LABAs)
Study: 14520721
Drug: Long-acting β2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-adrenoceptor agonists (LABAs) with regular maintenance with inhaled corticosteroids (ICS)
Study: 10944595
Drug: Adjuvant CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMF chemotherapy (given to 77 patients, 65%)
Study: 8349935
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg intranasal)
Study: 28822559
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (7 days of oral metronidazole and ciprofloxacin)
Study: 28822559
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care without antibiotics
Study: 24714011
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 μg plus 3 ml of 0.5% hyperbaric bupivacaine (Group FB)
Study: 24714011
Drug: Intrathecal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group TB)
Study: 24714011
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group SB)
Study: 19740393
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg alone
Study: 19740393
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg with omeprazole 40 mg (administered 15 min before imatinib on day 5)
Study: 19740393
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg with omeprazole 40 mg
Study: 14692022
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of Zoledronic acid (Zol)
Study: 14692022
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of Pamidronate (Pam)
Study: 11207631
Drug: Testosterone with
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone with 10 mg oestradiol (group 2, n = 7)
Study: 11207631
Drug: Testosterone with
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone with 20 mg oestradiol (group 3, n = 6)
Study: 2720925
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus gamma-globulin, 400 mg/kg/day for 4 consecutive days (n = 28, 60%)
Study: 2720925
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n = 19, 40%)
Study: 28945641
Drug: 4-week finger
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week finger grip training program (suspensions on small holds, 2 times a week)
Study: 15056989
Drug: Exercise Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Group (EG) - 1 hour of physical exercise twice a week for 5 months
Study: 15523434
Drug: Oil-based oral
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-based oral spray
Study: 15523434
Drug: Water-based oral
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based oral spray (placebo)
Study: 8747042
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (0.5 mg/day s.c.)
Study: 8747042
Drug: Low-dose leuprolide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leuprolide acetate depot (1.88 mg s.c.)
Study: 21868743
Drug: Androgen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen replacement therapy, aerobic physical activity, tadalafil administration
Study: 20200926
Drug: ALN 5
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 5 mg/day
Study: 10341016
Drug: ALN 10
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 10 mg/day
Study: 16286100
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily)
Study: 16230122
Drug: Corticosteroid (deflazacort,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (deflazacort, 30 mg daily) plus tamsulosin
Study: 7756099
Drug: Intravenous frusemide:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide: 40 mg bolus then 40 mg h‐1 for 3 h
Study: 7756099
Drug: Captopril: two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril: two 12.5 mg oral doses separated by 2 h
Study: 7756099
Drug: Combined dosing:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dosing: first captopril dose preceded the frusemide bolus by 30 min
Study: 26786987
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen therapy with Venturi mask for first 12 hours of admission